Rizact: Advanced Migraine Relief with Rizatriptan Benzoate
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 8 | $8.03 | $64.26 (0%) | 🛒 Add to cart |
| 12 | $7.45 | $96.39 $89.36 (7%) | 🛒 Add to cart |
| 24 | $6.94 | $192.77 $166.67 (14%) | 🛒 Add to cart |
| 36 | $6.53 | $289.16 $234.94 (19%) | 🛒 Add to cart |
| 60 | $6.12 | $481.94 $367.48 (24%) | 🛒 Add to cart |
| 88 | $5.82
Best per pill | $706.84 $512.06 (28%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 8 | $6.40 | $51.21 (0%) | 🛒 Add to cart |
| 12 | $6.02 | $76.81 $72.29 (6%) | 🛒 Add to cart |
| 24 | $5.61 | $153.62 $134.54 (12%) | 🛒 Add to cart |
| 36 | $5.22 | $230.43 $187.75 (19%) | 🛒 Add to cart |
| 60 | $4.82 | $384.04 $289.16 (25%) | 🛒 Add to cart |
| 88 | $4.62
Best per pill | $563.26 $406.63 (28%) | 🛒 Add to cart |
Rizact is a prescription medication specifically formulated for the acute treatment of migraine attacks with or without aura in adults. It is not indicated for the prophylactic management of migraine or for use in cluster headaches. Containing the active ingredient rizatriptan benzoate, a selective serotonin receptor agonist, Rizact targets the complex pathophysiology of migraine by constricting dilated cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides. This targeted mechanism offers patients a potent therapeutic option to alleviate debilitating migraine symptoms, including severe pain, photophobia, phonophobia, and nausea, facilitating a prompt return to normal function.
Features
- Active ingredient: Rizatriptan benzoate (10 mg per tablet)
- Formulation: Orally disintegrating tablets and standard film-coated tablets
- Rapid disintegration: Orally disintegrating formulation begins dissolution on the tongue without water
- Rapid absorption: Demonstrated Tmax of approximately 1-1.5 hours
- High bioavailability: Approximately 45%
- Excipients: Includes gelatin, mannitol, aspartame, and peppermint flavor (orally disintegrating tablet)
Benefits
- Provides rapid relief from acute migraine headache pain, often within 30 minutes for some patients.
- Effectively reduces or eliminates associated migraine symptoms, including nausea, vomiting, and sensitivity to light and sound.
- Offers a convenient, portable, and water-free administration option with the orally disintegrating tablet formulation.
- Empowers patients with a reliable and fast-acting treatment to abort a migraine attack, minimizing disruption to daily activities.
- Demonstrates a well-established efficacy and safety profile supported by extensive clinical data.
- Provides a therapeutic option for patients who have had unsatisfactory response to simpler analgesics.
Common use
Rizact is indicated for the acute treatment of migraine attacks with or without aura in adults. It is most effective when taken at the very onset of migraine symptoms. It is not intended for the prevention of migraines or for the management of hemiplegic or basilar migraines. The medication is used to abort an ongoing attack, and its use should be limited to treating an established migraine episode. It is not a treatment for other types of headache (e.g., tension-type headaches).
Dosage and direction
The recommended dose is a single 10 mg tablet. If the migraine headache returns, a second dose may be taken at least 2 hours after the first dose. The maximum dose in a 24-hour period should not exceed 30 mg. The orally disintegrating tablet should be placed on the tongue and allowed to dissolve, after which it may be swallowed with saliva. Administration with water is not necessary. The film-coated tablet should be swallowed whole with water. Efficacy may be diminished if taken during the aura phase before the headache pain begins. The safety of treating more than four headaches in a 30-day period has not been established.
Precautions
Rizact may cause dizziness or drowsiness. Patients should be advised to assess their individual tolerance before operating machinery or driving a motor vehicle. This medication should be used with caution in patients with risk factors for coronary artery disease (e.g., hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history) unless a cardiovascular evaluation provides satisfactory evidence of safety. There is a potential for serotonin syndrome, particularly with concomitant use of other serotonergic drugs. Patients should be monitored for signs of medication overuse headache, which can develop from using acute migraine treatments for 10 or more days per month.
Contraindications
Rizact is contraindicated in patients with:
- Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia)
- History of coronary artery vasospasm, including Prinzmetal’s angina
- Uncontrolled hypertension
- History of stroke or transient ischemic attack (TIA)
- Peripheral vascular disease
- Ischemic bowel disease
- Hypersensitivity to rizatriptan benzoate or any component of the formulation
- Concurrent administration or within 24 hours of use of another 5-HT1 agonist (e.g., another triptan) or an ergotamine-type medication (e.g., dihydroergotamine, methysergide)
- Concurrent administration or within 2 weeks of discontinuation of a monoamine oxidase (MAO) A inhibitor
Possible side effect
Common side effects (may affect up to 1 in 10 people) include:
- Dizziness, drowsiness, fatigue
- Sensations of pain or pressure in the chest, neck, throat, or jaw (typically non-cardiac)
- Nausea
- Dry mouth
- Paresthesia (tingling, warmth, or cold sensations)
Less common side effects include:
- Palpitations, tachycardia
- Flushing
- Asthenia (weakness)
- Dyskinesia (impaired voluntary movement)
- Hypertensive crisis (rare)
- Serotonin syndrome (rare, especially with concomitant SSRIs/SNRIs)
- Myocardial ischemia or infarction (rare)
Drug interaction
Significant drug interactions include:
- Monoamine Oxidase-A Inhibitors (MAOIs): Contraindicated. Concomitant use dramatically increases rizatriptan plasma levels and the risk of serotonin syndrome.
- Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Potential increased risk of serotonin syndrome (weakness, hyperreflexia, incoordination).
- Other 5-HT1 Agonists (Triptans) and Ergot Derivatives: Contraindicated due to additive vasoconstrictive effects.
- Propranolol: Co-administration increases the AUC of rizatriptan by 70%; a 5 mg dose of Rizact is recommended for patients taking propranolol.
- Drugs that are potent CYP450 inhibitors are not expected to significantly interact, as rizatriptan is primarily metabolized by monoamine oxidase-A.
Missed dose
Rizact is not taken on a scheduled basis; it is used only to treat an acute migraine attack as needed. Therefore, the concept of a “missed dose” does not apply. The medication should be taken as soon as possible after the onset of migraine pain. If a dose is not taken during an attack, it should simply be taken at the onset of the next qualifying migraine attack.
Overdose
Symptoms of overdose may be an exaggeration of the known effects of the drug, including severe dizziness, sedation, syncope, vasospasm, bradycardia, atrioventricular block, vomiting, and possibly serotonin syndrome. There is no specific antidote for rizatriptan overdose. Treatment consists of supportive measures, including continuous ECG monitoring for at least 20 hours and observation of the patient’s vital signs. Hemodialysis is unlikely to be beneficial due to the drug’s large volume of distribution.
Storage
Store Rizact tablets at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light and moisture. Keep the orally disintegrating tablets in the original blister package until the moment of use. Keep all medications out of the reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this product card.
Reviews
“Rizact has been a game-changer for managing my severe migraines. The ODT formulation is incredibly convenient when I’m on the go and the nausea makes swallowing a pill difficult. I experience significant relief within about 45 minutes, allowing me to get back to my workday.” – Sarah K., verified patient.
“As a neurologist, I find rizatriptan to be a cornerstone of acute migraine therapy. Rizact offers a reliable and fast-acting option for my patients. I particularly appreciate the availability of two formulations, which allows for personalized treatment based on patient preference and symptom profile.” – Dr. Evan R., Neurologist.
“While effective at stopping the pain, I did experience noticeable chest tightness and dizziness after taking it. It worked, but the side effects were concerning enough that my doctor and I decided to explore other options for my migraine management.” – Mark T., verified patient.
“From a pharmacy perspective, Rizact is a frequently dispensed and well-tolerated triptan. Patient counseling focuses on proper use—taking it at headache onset, the 2-hour re-dosing rule, and the importance of reporting any cardiac symptoms to their physician immediately.” – Jennifer L., PharmD.